You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Patent: 10,656,152


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,656,152
Title:Posterior segment drug delivery
Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.
Inventor(s): de Juan, Jr.; Eugene (Menlo Park, CA), Alster; Yair (Menlo Park, CA), Chamow; Steven M. (Menlo Park, CA), Farinas; Kathleen C. (Menlo Park, CA), Gifford, III; Hanson S. (Menlo Park, CA), Macfarlane; K. Angela (Menlo Park, CA), Reich; Cary J. (Menlo Park, CA), Barrett; Michael (Menlo Park, CA), Campbell; Randolph E. (Menlo Park, CA), George; Robert (Menlo Park, CA), Sutton; Douglas (Menlo Park, CA)
Assignee: ForSight Vision4, Inc. (South San Francisco, CA)
Application Number:15/807,396
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Claims and Patent Landscape of US Patent 10,656,152

Introduction

When analyzing a patent, particularly one like US Patent 10,656,152, it is crucial to delve into the intricacies of the patent claims, the determination of inventorship, and the broader patent landscape. This analysis will help in understanding the legal boundaries, the innovative contributions, and the strategic implications of the patent.

Determining Inventorship

Inventorship is a critical aspect of patent law, as it determines who is entitled to the patent. According to US patent law, an inventor is someone who conceives the subject matter of at least one claim of the patent. This conception must be a "definite and permanent idea of the complete and operative invention" that can be reduced to practice by one with ordinary skill in the field without extensive research or experimentation[1].

  • Conception vs. Reduction to Practice: It is important to distinguish between the conception of an idea and the reduction of that idea to practice. Only those who contribute to the conception of the invention are considered inventors, not those who merely reduce the invention to practice using ordinary skill[1].

Patent Claims Analysis

Patent claims are the heart of a patent application, defining the legal boundaries of the invention.

Clarity and Specificity

The claims must be sufficiently clear and particularly point out and distinctly define the subject matter that will be protected by the patent grant. This clarity is essential to avoid issues under 35 USC ยง112(b)[4].

Hierarchy and Structure

Modern patent applications often include a large number of claims, sometimes in the hundreds or even thousands. The claims are typically arranged in a hierarchical structure, with independent claims and dependent claims. Tools like the Patent Matrix software can help in parsing and analyzing these claims efficiently[2].

Novelty and Nonobviousness

For a patent to be granted, the claimed invention must be novel and nonobvious. The invention cannot be the same as something known in the prior art, and it must not be an obvious extension of the prior art. The USPTO examines these requirements rigorously to ensure that only innovative and unique inventions are patented[5].

The Leahy-Smith America Invents Act (AIA)

The AIA, enacted in 2011, significantly altered the US patent landscape. It introduced the Patent Trial and Appeal Board (PTAB) and new administrative challenges to patent validity, such as Inter Partes Review (IPR).

  • PTAB and IPR: These mechanisms allow for post-grant review of patents, providing a more efficient and cost-effective way to challenge patent validity compared to traditional litigation. This has implications for the enforcement and defense of patents like US Patent 10,656,152[3].

Patent Eligibility

The AIA and subsequent guidelines have refined the criteria for patent eligibility. The Alice/Mayo test is used to determine if a patent claim is directed to an ineligible concept, such as a law of nature, natural phenomenon, or abstract idea. If so, the claim must contain an "inventive concept" that transforms the nature of the claim into a patent-eligible application[3].

The Role of Technology in Patent Applications

Technology has both driven and facilitated the increase in patent applications. Tools for automated importing, parsing, and analyzing patent claims have become essential in managing the complexity of modern patent applications. This technological advancement helps in rapidly reviewing claims, which is crucial given the annual growth rate of approximately 11% in patent applications[2].

Strategic Implications

Understanding the claims and the broader patent landscape is vital for strategic decision-making.

  • Competitive Positioning: With the increasing number of patent applications, it is challenging to understand and communicate one's patent property and competitive position. Analyzing the claims of US Patent 10,656,152 in the context of prior art and existing patents can help in identifying potential competitors and opportunities for innovation[2].

  • Litigation and Enforcement: The clarity and specificity of patent claims are crucial in litigation and enforcement. Clear claims help in avoiding disputes and ensure that the patent holder can effectively enforce their rights against infringers[5].

Case Law and Precedents

Case law plays a significant role in shaping patent law and practice. For example, the Festo Corporation v. Shoketsu Kinzoku Kogyo Kabushiki Co. Ltd. case has influenced the interpretation of claims and the doctrine of equivalents, highlighting the importance of careful claim drafting to avoid limitations during patent prosecution[2].

Best Practices in Patent Drafting

A well-written patent application should describe the invention so that one of ordinary skill can understand, make, and use it. It is important to define special claim terms explicitly and avoid narrow characterizations that could limit the scope of the patented claims[4].

Conclusion

Analyzing the claims and patent landscape of US Patent 10,656,152 involves a deep dive into inventorship, claim clarity, novelty, nonobviousness, and the broader legal and technological context. Here are some key takeaways:

  • Inventorship: Focuses on the conception of the invention, not the reduction to practice.
  • Claim Clarity: Essential for defining the legal boundaries of the invention.
  • Novelty and Nonobviousness: Critical requirements for patentability.
  • AIA and PTAB: Significant changes in post-grant review mechanisms.
  • Technological Facilitation: Tools for automated claim analysis are vital.
  • Strategic Implications: Understanding claims is crucial for competitive positioning and litigation.

FAQs

  1. What is the significance of conception in determining inventorship?

    • Conception is the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention. It is the key factor in determining who is an inventor[1].
  2. How do the claims in a patent application define the invention?

    • The claims define the legal boundaries of the invention, and they must be sufficiently clear and specific to point out and distinctly define the subject matter protected by the patent[4].
  3. What is the role of the Leahy-Smith America Invents Act (AIA) in patent law?

    • The AIA introduced significant changes, including the creation of the Patent Trial and Appeal Board (PTAB) and new administrative challenges to patent validity, such as Inter Partes Review (IPR)[3].
  4. Why is novelty a fundamental requirement for patentability?

    • Novelty ensures that the claimed invention is new and not already disclosed in the prior art. This requirement prevents the patenting of existing knowledge[5].
  5. How does technology impact the patent application process?

    • Technology facilitates the patent application process through tools for automated importing, parsing, and analyzing patent claims, helping to manage the increasing complexity and volume of patent applications[2].

Sources

  1. Determining Inventorship for US Patent Applications - Oregon State University
  2. Patent Claims Analysis System and Method - Google Patents
  3. The Patent Trial and Appeal Board and Inter Partes Review - Congressional Research Service
  4. Drafting a Provisional Application - USPTO
  5. Patent Law: A Handbook for Congress - Congressional Research Service

More… ↓

⤷  Subscribe

Details for Patent 10,656,152

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Emd Serono, Inc. PERGONAL menotropins For Injection 017646 August 22, 1975 ⤷  Subscribe 2029-01-29
Emd Serono, Inc. PERGONAL menotropins For Injection 017646 May 20, 1985 ⤷  Subscribe 2029-01-29
Eli Lilly And Company HUMATROPE somatropin For Injection 019640 June 23, 1987 ⤷  Subscribe 2029-01-29
Eli Lilly And Company HUMATROPE somatropin For Injection 019640 October 16, 1986 ⤷  Subscribe 2029-01-29
Eli Lilly And Company HUMATROPE somatropin For Injection 019640 February 04, 1999 ⤷  Subscribe 2029-01-29
Emd Serono, Inc. SAIZEN somatropin For Injection 019764 October 08, 1996 ⤷  Subscribe 2029-01-29
Emd Serono, Inc. SAIZEN somatropin For Injection 019764 August 29, 2000 ⤷  Subscribe 2029-01-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.